What is the price target for XFOR stock?
9 analysts have analysed XFOR and the average price target is 9.52 USD. This implies a price increase of 157.99% is expected in the next year compared to the current price of 3.69.
X4 PHARMACEUTICALS INC (XFOR) Forecast, Price Target & Analyst Ratings
NASDAQ:XFOR • US98420X2027
Current stock price
3.69 USD
-0.19 (-4.9%)
At close:
3.69 USD
0 (0%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for X4 PHARMACEUTICALS INC (XFOR).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- Mar 23, 2026
- Period
- Q4 / 2025
- EPS Estimate
- -$0.35
- Revenue Estimate
- 1.768M
Price Target Details & History
Consensus Price Target and Range
Mean target
$9.52
Upside
+ 157.99%
From current price of $3.69 to mean target of $9.52, Based on 9 analyst forecasts
Low
$5.05
Median
$10.20
High
$13.65
Price Target Revisions
1 Month
16.67%
3 Months
16.67%
Price Target Summary
9 Wall Street analysts provided a forecast for the next 12 months for XFOR. The average price target is 9.52 USD. This implies a price increase of 157.99% is expected in the next year compared to the current price of 3.69.
The average price target has been revised upward by 16.67% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
84.44%
XFOR was analyzed by 9 analysts. The buy percentage consensus is at 84. So analysts seem to be very confident about XFOR.
In the previous month the buy percentage consensus was at a similar level.
XFOR was analyzed by 9 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-09 | Guggenheim | Initiate | Buy |
| 2025-12-05 | Stifel | Maintains | Buy -> Buy |
| 2025-11-10 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-08-29 | Stifel | Maintains | Buy -> Buy |
| 2025-08-13 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-05-02 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-03-27 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-26 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2025-02-07 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-14 | Stifel | Maintains | Buy -> Buy |
| 2024-11-14 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-06-28 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-31 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-04-30 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-03-22 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-12-12 | B. Riley Securities | Downgrade | Buy -> Neutral |
| 2023-08-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-05-17 | Stifel | Maintains | Buy -> Buy |
| 2023-05-05 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-04-10 | B. Riley Securities | Maintains | Buy |
| 2023-03-24 | Oppenheimer | Maintains | Outperform |
| 2023-03-22 | Cantor Fitzgerald | Maintains | Overweight |
| 2023-03-22 | HC Wainwright & Co. | Maintains | Buy |
| 2022-12-22 | Cantor Fitzgerald | Initiate | Overweight |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- Mar 23, 2026
- Period
- Q4 / 2025
- EPS Estimate
- -$0.35
- Revenue Estimate
- 1.768M
- Revenue Q2Q
- 23.29%
- EPS Q2Q
- 94.09%
- Number of Analysts
- 6
Next Earnings Revisions
Revenue (1 Month)
3.33%
Revenue (3 Months)
-12.82%
EPS (1 Month)
3.47%
EPS (3 Months)
7.33%
Next Earnings Summary
XFOR is expected to report earnings on 3/23/2026. The consensus EPS estimate for the next earnings is -0.35 USD and the consensus revenue estimate is 1.77M USD.
The next earnings revenue estimate has been revised downward by 12.82% in the past 3 months. Downward revisions are a negative sign and indicate that analysts are more pessimistic about the next earnings compared to 3 months ago.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 2.557M | 34.876M 1,263.94% | 11.471M -67.11% | 23.93M 108.61% | 116.09M 385.12% | 297.02M 155.85% | 589.21M 98.37% | 256.24M -56.51% | 622.58M 142.97% | |||
| EBITDA YoY % growth | -87.57M -16.99% | -107.103M -22.31% | -140.605M -31.28% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -88.08M -16.89% | -107.522M -22.07% | -141.401M -31.51% | -89.569M 36.66% | -104.389M -16.55% | -110.151M -5.52% | -41.756M 62.09% | 85.202M 304.05% | 282.6M 231.68% | 199.28M -29.48% | 336.02M 68.62% | |
| Operating Margin | N/A | N/A | -5,529.96% | -256.82% | -910.03% | -460.30% | -35.97% | 28.69% | 47.96% | 77.77% | 53.97% | |
| EPS YoY % growth | -56.10 49.46% | -18.00 67.91% | -21.30 -18.33% | -2.73 87.17% | -1.11 59.45% | -1.05 5.22% | -0.38 63.59% | 0.53 238.67% | 1.74 227.88% | 0.87 -50.15% | 2.67 208.24% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.35 94.09% | -0.23 -686.50% | -0.24 93.14% | -0.24 65.51% | -0.24 32.85% |
| Revenue Q2Q % growth | 1.768M 23.29% | 4.998M -82.65% | 2.618M 32.69% | 2.72M 54.11% | 2.958M 67.31% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -25.489M 28.63% | -22.644M -139.80% | -22.733M 13.34% | -22.369M 18.69% | -21.864M 14.22% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
24.95%
EPS Next 5 Year
15.15%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
120.47%
Revenue Next 5 Year
165.94%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
X4 PHARMACEUTICALS INC / XFOR Forecast FAQ
What is the next earnings date for XFOR stock?
X4 PHARMACEUTICALS INC (XFOR) will report earnings on 2026-03-23, after the market close.
What are the consensus estimates for XFOR stock next earnings?
The consensus EPS estimate for the next earnings of X4 PHARMACEUTICALS INC (XFOR) is -0.35 USD and the consensus revenue estimate is 1.77M USD.
How many analysts have analysed X4 PHARMACEUTICALS INC (XFOR)?
The number of analysts covering X4 PHARMACEUTICALS INC (XFOR) is 9.